Literature DB >> 29478838

Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon.

Fabian K Berger1, Sari S Rasheed2, George F Araj3, Rami Mahfouz3, Hussein H Rimmani4, Walid R Karaoui4, Ala I Sharara4, Ghassan Dbaibo5, Sören L Becker6, Lutz von Müller7, Markus Bischoff8, Ghassan M Matar2, Barbara Gärtner8.   

Abstract

Clostridium (Clostridioides) difficile is the main cause for nosocomial diarrhoea in industrialised nations. Epidemiologic data on the pathogen's occurrence in other world regions are still scarce. In this context we characterized with phenotypic and molecular genetic methods C. difficile isolates stemming from hospitalised patients with diarrhoea in Lebanon. From 129 stool samples of symptomatic patients at a tertiary care University hospital in Lebanon, a total of 107 C. difficile strains were cultivated and underwent ribotyping, toxin gene detection and antibiotic resistance testing. Ribotype 014 (RT014, 16.8%) predominated, followed by RT002 (9.3%), RT106 (8.4%) and RT070 (6.5%). Binary toxin gene-positive isolates (RT023, RT078 and RT126) were rarely detected and RT027 was absent. Interestingly, within one isolate only the toxin A gene (tcdA) was detected. Multiple-locus variable-number tandem repeat analysis (MLVA) revealed strong strain diversity in most RTs. The isolates were sensitive to metronidazole and vancomycin, and only a small proportion of strains displayed resistance against moxifloxacin, rifampicin, and clarithromycin (5.6%, 1.9%, and 2.8%), respectively. The data indicate that the genetic strain composition of Lebanese strains differs markedly from the situation seen in Europe and North America. Especially the epidemic RTs seen in the latter regions were almost absent in Lebanon. Interestingly, most strains showed almost no resistance to commonly used antibiotics that are suspected to play a major role in the development of C. difficile infection, despite frequent use of these antibiotics in Lebanon. Thus, the role of antimicrobial resistance as a major driving force for infection development remains uncertain in this area.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  BI/NAP1/027; Distribution; Epidemiology; MLST; Middle East; Prevalence

Mesh:

Substances:

Year:  2018        PMID: 29478838     DOI: 10.1016/j.ijmm.2018.01.004

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  9 in total

1.  Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain.

Authors:  T J Carlson; D Blasingame; A J Gonzales-Luna; F Alnezary; K W Garey
Journal:  Anaerobe       Date:  2019-12-19       Impact factor: 3.331

2.  Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study.

Authors:  Masoumeh Azimirad; Marcela Krutova; Abbas Yadegar; Shabnam Shahrokh; Meysam Olfatifar; Hamid Asadzadeh Aghdaei; Warren N Fawley; Mark H Wilcox; Mohammad Reza Zali
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

3.  Prevalence and Strain Characterization of Clostridioides (Clostridium) difficile in Representative Regions of Germany, Ghana, Tanzania and Indonesia - A Comparative Multi-Center Cross-Sectional Study.

Authors:  Mwanaisha Seugendo; Iryna Janssen; Vanessa Lang; Irene Hasibuan; Wolfgang Bohne; Paul Cooper; Rolf Daniel; Katrin Gunka; R L Kusumawati; Stephen E Mshana; Lutz von Müller; Benard Okamo; Jan R Ortlepp; Jörg Overmann; Thomas Riedel; Maja Rupnik; Ortrud Zimmermann; Uwe Groß
Journal:  Front Microbiol       Date:  2018-08-07       Impact factor: 5.640

4.  High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.

Authors:  Laura Tijerina-Rodríguez; Licet Villarreal-Treviño; Simon D Baines; Rayo Morfín-Otero; Adrián Camacho-Ortíz; Samantha Flores-Treviño; Héctor Maldonado-Garza; Eduardo Rodríguez-Noriega; Elvira Garza-González
Journal:  PLoS One       Date:  2019-07-31       Impact factor: 3.240

5.  Clostridioides (Clostridium) difficile Pacemaker Infection.

Authors:  Anna Berkefeld; Fabian K Berger; Barbara C Gärtner; Nina Wantia; Anatol Prinzing; Karl-Ludwig Laugwitz; Dirk H Busch; Kathrin Rothe
Journal:  Open Forum Infect Dis       Date:  2020-10-14       Impact factor: 3.835

6.  Phenotypical and Genotypical Comparison of Clostridium difficile Isolated from Clinical Samples: Homebrew DNA Fingerprinting versus Antibiotic Susceptibility Testing (AST) and Clostridial Toxin Genes.

Authors:  Javid Sisakhtpour; Fatemeh Savaheli Moghadam; Sepideh Khodaparast; Nima Khoramabadi; Ashraf Mohabati Mobarez
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-12-02       Impact factor: 2.471

7.  Antigen-Specific vs. Neutralizing Antibodies Against Conditioned Media of Patients With Clostridioides difficile Infection: A Prospective Exploratory Study.

Authors:  Sophie Roth; Philipp Jung; James Boone; Alexander Mellmann; Anna Nimmesgern; Sören L Becker; Fabian K Berger; Lutz von Müller
Journal:  Front Microbiol       Date:  2022-02-24       Impact factor: 5.640

8.  Significance of Clostridium difficile in community-acquired diarrhea in a tertiary care center in Lebanon.

Authors:  Reem Al Assaad; Alik Dakessian; Rana Bachir; Abdul Rahman Bizri; Mazen El Sayed
Journal:  Sci Rep       Date:  2020-03-30       Impact factor: 4.379

9.  Toxin profiles and antimicrobial resistance patterns among toxigenic clinical isolates of Clostridioides (Clostridium) difficile.

Authors:  Hamid Heidari; Hadi Sedigh Ebrahim-Saraie; Ali Amanati; Mohammad Motamedifar; Nahal Hadi; Abdollah Bazargani
Journal:  Iran J Basic Med Sci       Date:  2019-07       Impact factor: 2.699

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.